Her2+ advanced gastric cancer. EMA recommends approval of trastuzumab deruxtecan for pre-treated patients

The positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency is based on the results of two studies, DESTINY-Gastric02 and DESTINY-Gastric01, which respectively demonstrated clinically significant efficacy and an improvement in overall survival of trastuzumab deruxtecan compared to chemotherapy. 18 NOV – The Committee for Medicinal Products for … Read more